| Literature DB >> 35902458 |
Emily Rimmer1,2,3, Allan Garland4,5, Anand Kumar5,6, Steve Doucette7, Brett L Houston8,9, Chantalle E Menard8,9, Murdoch Leeies4,5, Alexis F Turgeon10,11, Salah Mahmud4, Donald S Houston8,9, Ryan Zarychanski4,8,9,5.
Abstract
PURPOSE: Septic shock is associated with a mortality of 20-40%. The white blood cell count (WBC) at hospital admission correlates with prognosis in septic shock. Here, we explore whether the trajectory of WBC after admission provides further information about outcomes. We aimed to identify groups of patients with different WBC trajectories and the association of WBC trajectory with mortality.Entities:
Keywords: Septic shock; trajectory analysis; white blood cell count
Mesh:
Year: 2022 PMID: 35902458 PMCID: PMC9334545 DOI: 10.1007/s12630-022-02282-5
Source DB: PubMed Journal: Can J Anaesth ISSN: 0832-610X Impact factor: 6.713
Baseline characteristics of the entire cohort and each WBC trajectory group
| Entire cohort | WBC trajectory groups | |||||||
|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | ||
| General demographics | ||||||||
| Male sex, | 454/917 (49.5%) | 178/325 (54.8%) | 31/57 (54.4%) | 163/329 (49.5%) | 55/130 (42.3%) | 9/27 (33.3%) | 17/42 (40.5%) | 1/7 (14.3%) |
| Age (yr), mean (SD) | 60.9/917 (16.5) | 60.7 (16.5) | 57.1 (17.1) | 62.3 (16.6) | 60.2 (15.5) | 58.4 (15.3) | 60.3 (17.8) | 53.1 (21.1) |
| Duration of hospitalization before shock (days), median [IQR] | 1 [0–2] | 1 [0–3] | 1 [0–2] | 0.82 [0–2] | 0.95 [0–2] | 0.89 [0–2] | 1 [0–4] | 0 [0–3] |
| APACHE II score, mean (SD) | 23.7 (7.2) | 22.7 (7) | 24.5 (8.1) | 23.2 (6.9) | 25.3 (7.2) | 26.7 (7.5) | 26 (7.7) | 27.7 (5.8) |
| Time to 1st antibiotic (hr), median [IQR] | 2 [0.03–6] | 2.6 [0.4–6.3] | 1.2 [0–5.7] | 1.6 [0.02–5.6] | 1.3 [0–4.2] | 2.8 [0–6.4] | 1.4 [0.08–4] | 16.4 [0–71.2] |
| Appropriate antibiotic use, | 816/917 (89%) | 286/325 (88%) | 50/57 (87.7%) | 296/329 (90%) | 114/130 (87.7%) | 24/27 (88.9%) | 41/42 (97.6%) | 5/7 (71.4%) |
| Geographic distribution | ||||||||
| Center 1, | 526/917 (57.4%) | 192/325 (59.1%) | 31/57 (54.4%) | 186/329 (56.5%) | 77/130 (59.2%) | 13/27 (48.1%) | 23/42 (54.8%) | 4/7 (57.1%) |
| Center 2, | 391/917 (42.6%) | 133/325 (40.9%) | 26/57 (45.6%) | 143/329 (43.5%) | 53/130 (40.8%) | 14/27 (51.9%) | 19/42 (45.2%) | 3/7 (42.9%) |
| Pre-existing medical conditions, | ||||||||
| Chronic obstructive pulmonary disease | 141/917 (15.4%) | 44/325 (13.5%) | 11/57 (19.3%) | 54/329 (16.4%) | 24/130 (18.5%) | 0/27 (0%) | 8/42 (19%) | 0/7 (0%) |
| Diabetes mellitus | 366/917 (39.9%) | 124/325 (38.2%) | 17/57 (29.8%) | 129/329 (39.2%) | 67/130 (51.5%) | 10/27 (37%) | 18/42 (42.9%) | 1/7 (14.3%) |
| Chronic kidney disease | 138/917 (15) | 55/325 (16.9%) | 7/57 (12.3%) | 44/329 (13.4%) | 19/130 (14.6%) | 4/27 (14.8%) | 8/42 (19%) | 1/7 (14.3%) |
| Dialysis dependence | 114/917 (12.4%) | 45/325 (13.8%) | 5/57 (8.8%) | 40/329 (12.2%) | 15/130 (11.5%) | 1/27 (3.7%) | 7/42 (16.7%) | 1/7 (14.3%) |
| NYHA class IV heart failure | 6/917 (0.7%) | 5/325 (1.5%) | 0/57 (0%) | 1/329 (0.3%) | 0/130 (%) | 0/27 (0%) | 0/42 (0%) | 0/7 (0%) |
| Physiologic and laboratory variables on admission, median [IQR] | ||||||||
| Platelets (× 109·L-1) | 183 [118–259] | 165 [106–224] | 164 [107–245] | 186.5 [128–266.5] | 216 [159–313] | 186.5 [87–312] | 213 [122–339] | 272 [154–311] |
| Serum creatinine (µMol⋅L-1) | 175 [98–329] | 164 [90–338.5] | 200 [117–262] | 170 [101–311] | 192 [98–351] | 206 [113–294] | 206 [105–314] | 160 [94–356] |
| INR | 1.4 [1.2–1.7] | 1.4 [1.2–1.7] | 1.4 [1.2–1.6] | 1.4 [1.2–1.7] | 1.4 [1.2–1.7] | 1.4 [1.3–1.9] | 1.4 [1.2–2] | 1.8 [1.4–1.9] |
| Bilirubin (µMol·L-1) | 11.4 [7–23] | 11 [7–22] | 15.5 [8–24] | 12 [6–24] | 12 [7–32] | 10 [7–23] | 9 [7–17] | 10 [5–41] |
| HCO3 (mEq·L-1) | 19 [16–23] | 19.5 [16–23] | 20 [16–22] | 19 [16–23] | 18.8 [15.9–22] | 19 [17–22] | 18 [14–19.5] | 20 [12–21] |
| Source of sepsis, | ||||||||
| Culture positive | 605/917 (65.9%) | 198/325 (60.9%) | 45/57 (78.9%) | 214/329 (65%) | 94/130 (72.3%) | 15/27 (55.5%) | 32/42 (76.2%) | 7/7 (100%) |
| Bacteremia | 214/917 (23.3%) | 70/325 (21.5%) | 13/57 (22.8%) | 83/329 (25.2%) | 27/130 (20.8%) | 8/27 (29.6%) | 12/42 (28.6%) | 1/7 (14.3%) |
| Catheter-related infection | 16/917 (1.7%) | 8/325 (2.5%) | 0/57 (0%) | 6/329 (1.8%) | 1/130 (0.8%) | 1/27 (3.7%) | 0/42 (0%) | 0/7 (0%) |
| Respiratory | 324/917 (35.3%) | 121/325 (37.2%) | 22/57 (38.6%) | 105/329 (31.9%) | 52/130 (40%) | 12/27 (44.4%) | 9/42 (21.4%) | 3/7 (42.9%) |
| Urinary tract | 96/917 (10.5%) | 22/325 (6.8%) | 1/57 (1.8%) | 47/329 (14.3%) | 11/130 (8.5%) | 5/27 (18.5%) | 10/42 (23.8%) | 0/7 (0%) |
| Intra-abdominal | 290/917 (31.6%) | 102/325 (31.4%) | 23/57 (40.4%) | 111/329 (33.7%) | 30/130 (23.1%) | 5/27 (18.5%) | 16/42 (38.1%) | 3/7 (42.9%) |
| CNS | 10/917 (1.1%) | 1/325 (0.3%) | 0/57 (0%) | 3/329 (0.9%) | 5/130 (3.8%) | 1/27 (3.7%) | 0/42 (0%) | 0/7 (0%) |
| Skin and soft tissue | 124/917 (13.5%) | 43/325 (13.2%) | 8/57 (14%) | 40/329 (12.2%) | 24/130 (18.5%) | 2/27 (7.4%) | 6/42 (14.3%) | 1/7 (14.3%) |
| Surgical site | 8/917 (0.9%) | 5/325 (1.5%) | 1/57 (1.8%) | 0/329 (0%) | 2/130 (1.5%) | 0/27 (0%) | 0/42 (0%) | 0/7 (0%) |
| Cardiac/pericardial | 3/917 (0.3%) | 1/325 (0.3%) | 0/57 (0%) | 2/329 (0.6%) | 0/130 (0%) | 0/27 (0%) | 0/42 (0%) | 0/7 (0%) |
| Other | 19/917 (2.1%) | 9/325 (2.8%) | 2/57 (3.5%) | 3/329 (0.9%) | 4/130 (3.1%) | 1/27 (3.7%) | 0/42 (0%) | 0/7 (0%) |
| Type of infection, | ||||||||
| Gram-positive organism | 254/917 (28.3%) | 76/325 (23.8%) | 25/57 (44.6%) | 93/329 (28.7%) | 41/130 (33.1%) | 9/27 (33.3%) | 8/42 (19%) | 2/7 (28.6%) |
| Gram-negative organism | 258/917 (28.7%) | 90/325 (28.2%) | 13/57 (23.2%) | 95/329 (29.3%) | 34/130 (27.4%) | 4/27 (14.8%) | 20/42 (47.6%) | 2/7 (28.6%) |
| Fungal | 35/917 (3.9%) | 12/325 (3.8%) | 5/57 (8.9%) | 10/329 (3.1%) | 5/130 (4%) | 1/27 (3.7%) | 1/42 (2.4%) | 1/7 (14.3%) |
| Other | 40/917 (4.4%) | 14/325 (4.4%) | 1/57 (1.8%) | 11/329 (3.4%) | 8/130 (6.5%) | 1/27 (3.7%) | 3/42 (7.1%) | 2/7 (28.6%) |
| New organ failures* on admission, | ||||||||
| Renal failure | 509/917 (55.5%) | 171/325 (52.6%) | 39/57 (68.4%) | 173/329 (52.6%) | 74/130 (56.9%) | 19/27 (70.4%) | 28/42 (66.7%) | 5/7 (71.4%) |
| Hematologic failure | 113/917 (12.3%) | 49/325 (15.1%) | 9/57 (15.8%) | 32/329 (9.7%) | 13/130 (10%) | 5/27 (18.5%) | 4/42 (9.5%) | 1/7 (14.3%) |
| Hepatic failure | 145/917 (15.8%) | 43/325 (13.2%) | 10/57 (17.5%) | 54/329 (16.4%) | 29/130 (22.3%) | 5/27 (18.5%) | 3/42 (7.1%) | 1/7 (14.3%) |
| Respiratory failure | 733/917 (79.9%) | 268/325 (82.5%) | 52/57 (91.2%) | 253/329 (76.9%) | 100/130 (76.9%) | 22/27 (81.5%) | 33/42 (78.6%) | 5/7 (71.4%) |
| CNS failure | 292/917 (31.8%) | 111/325 (34.2%) | 15/57 (26.3%) | 100/329 (30.4%) | 44/130 (33.8%) | 10/27 (37%) | 10/42 (23.8%) | 2/7 (28.6%) |
| Coagulation failure | 315/917 (34.4%) | 106/325 (32.6%) | 17/57 (29.8%) | 106/329 (32.2%) | 53/130 (40.8%) | 11/27 (40.7%) | 18/42 (42.9%) | 4/7 (57.1%) |
| Metabolic failure | 391/917 (42.6%) | 122/325 (37.5%) | 31/57 (54.4%) | 137/329 (41.6%) | 57/130 (43.8%) | 14/27 (51.9%) | 27/42 (64.3%) | 3/7 (42.9%) |
| Total number of day one organ failures, mean (SD) | 3.7 (1.4) | 3.7 (1.4) | 4 (1.2) | 3.6 (1.5) | 3.8 (1.5) | 4.2 (1.5) | 3.9 (1.5) | 4 (1.9) |
*Organ failure definitions (cardiovascular = systolic blood pressure < 90 mm Hg or more than 40 mm Hg drop from normal OR MAP < 65 mm Hg for at least one hour despite adequate fluid resuscitation [2 L saline or equivalent] OR the use of vasopressors; renal = elevation of normal baseline creatinine to > 1.5 × normal value; respiratory = ventilation required; hematologic = platelet count < 80 × 109·L-1; metabolic = lactate > 3 mMol·L-1)
APACHE II = acute physiology and chronic health evaluation II; CNS = central nervous system; HCO3 = bicarbonate; INR = international normalized ratio; IQR = interquartile range; MAP = mean arterial pressure; NYHA = New York Heart Association; SD = standard deviation; WBC = white blood cell count
Fig. 1Graphical representation of the seven-group model of white blood cell count (WBC) in septic shock for seven days after intensive care unit admission
Results of multivariable Cox proportional hazard model assessing the effect of WBC trajectory group on 30-day mortality
| WBC trajectory group | Hazard ratio* (95% CI) | Adjusted | |
|---|---|---|---|
| Group 1 (ref) normal, flat | ref | ref | ref |
| Group 2 normal, rising | 1.45 (0.83 to2.53) | 0.19 | 0.56 |
| Group 3 moderate, decreasing | 1.13 (0.81 to 1.59) | 0.46 | 0.56 |
| Group 4 high, decreasing | 0.83 (0.5 to 1.37) | 0.47 | 0.56 |
| Group 5 high, rising | 3.41 (1.86 to 6.26) | < 0.001 | < 0.001 |
| Group 6 high, rapid decrease | 1.42 (0.69 to 2.91) | 0.34 | 0.56 |
| Group 7 significantly elevated | 1.46 (0.35 to 6.12) | 0.60 | 0.60 |
*Adjusted for age, sex, APACHE II score, baseline comorbidities, type of infection, site, antibiotic timing and type
†Adjusted for false discovery rate using Simes’ step-up procedure
APACHE II = acute physiology and chronic health evaluation II; CI = confidence interval; WBC = white blood cell count
Fig. 2Kaplan–Meier curve showing time to death among different WBC trajectory groups to a maximum of 30 days. Group 5 (high, rising) has the worst survival compared with other groups (P < 0.01). WBC = white blood cell count